REG - Immupharma PLC - Admission today to trading on Euronext Growth

ImmuPharmaAnnouncement

19/12/2019 07:05

RNS Number : 2964X
Immupharma PLC
19 December 2019
 


RNS | 19 December 2019
 
ImmuPharma PLC
("ImmuPharma" or the "Company")
 
Admission today to trading on Euronext Growth Brussels
ImmuPharma PLC (LSE:IMM | Euronext Growth: ALIMM), a specialist drug discovery and development company, is pleased to announce that, this morning at approximately 09.00am (GMT), ImmuPharma will commence trading on Euronext Growth Brussels ("Euronext") under ticker 'ALIMM'.
This new listing does not affect the trading of ImmuPharma's shares on AIM, nor is there any intention from the Company to raise additional funds from either AIM or Euronext.
The dual listing on Euronext Growth Brussels aims to further increase the visibility of ImmuPharma's shares with European investors, aligned with the investment thesis for ImmuPharma and specifically Lupuzor™ being repositioned, following the Company's recent deal with US Avion Pharmaceuticals, who are funding an international Phase III trial for ImmuPharma's lead programme, Lupuzor™. ImmuPharma looks forward to providing further progress updates on the Phase III program with Avion, as well as entering into additional partnerships outside of the US.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")



 
For further information please contact:
 



ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chairman


+ 44 (0) 207 152 4080




Dimitri Dimitriou, Chief Executive Officer








Lisa Baderoon, Head of Investor Relations


+ 44 (0) 7721 413496
 




 
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Vassil Kirtchev
 
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes
 
SI Capital (Joint Broker)
Nick Emerson
 


 
+44 (0) 203 368 8974
 
 
 
+44 (0) 203 815 8880
 
 
+44 (0) 1483 413500
 
 







4Reliance (Euronext Growth Listing Sponsor)
Jean-Charles Snoy
 
Degroof Petercam (Liquidity Provider)
Erik De Clippel
 
Backstage Communication
Olivier Duquaine
Jean-Louis Dubrule


+32 (0) 2 747 02 60
 
 
 
+32 (0) 477 504 784
+32 (0) 497 50 84 03
 






+32 (0) 2 747 02 60
 
 
+32 (0) 2 287 95 34
 
 
 
+32 (0) 477 504 784
+32 (0) 497 50 84 03

















 
 
Notes to Editors
 
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, LupuzorTM, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 29 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US. For additional information about ImmuPharma please visit www.immupharma.com.
 
About Avion Pharmaceuticals
Avion Pharmaceuticals, LLC is a US-based specialty pharmaceutical company formed to develop, acquire and market a portfolio of innovative pharmaceutical products in the Women's Health and other therapeutic categories aligned with our mission to improve the quality of patient lives. Avion Pharmaceuticals focuses on identifying opportunities to develop, acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfil unmet medical needs. For additional information about Avion Pharmaceuticals, visit www.avionrx.com.
 
About Lupuzor™ and Lupus
Lupuzor™ is ImmuPharma's lead compound, a peptide therapeutic and a first-in class autophagy immunomodulator for systemic lupus erythematosus (SLE or lupus) a potentially life-threatening auto-immune disease. Lupus is a chronic inflammatory disease which is thought to affect some 5 million individuals worldwide. The current standard of care still consists of drugs which have many side-effects and limited efficacy. Despite the need for an effective treatment, only one new therapy, namely GlaxoSmithKline's Benlysta, has been approved to treat the condition over the past 50 years. As such, there clearly exists an unmet medical need for a drug that has a strong efficacy and safety profile.
 
About Euronext
Euronext is the leading pan-European exchange, covering Belgium, France, Ireland, The Netherlands, Norway, Portugal and the UK. With close to 1,500 listed issuers worth €4.3 trillion in market capitalisation as of end September 2019, Euronext has an unmatched blue chip franchise that includes 26 issuers in the Morningstar® Eurozone 50 Index℠ and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM and Euronext AccessTM, simplifying access to listing for SMEs.  The Norwegian stock exchange and its clearing & settlement subsidiary, together operating as Oslo Børs VPS, joined Euronext on 17 June 2019. 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEANAPFESNFEF